Sarepta Therapeutics
SRPT
£15.46
Share price
-3.66%
Change (1 day)
-83.28%
Change (1 year)
Categories
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.
Sarepta Therapeutics (SRPT) Fails to deliver data
Key failure to deliver metrics for Sarepta Therapeutics :
- Last SEC data release: 2025-05-30
- Last 15 days FTD volume: £0.33 M
- Last 3 months FTD volume: £9.57 M
- Last year FTD volume: £9.57 M
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for Sarepta Therapeutics (SRPT) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for Sarepta Therapeutics (SRPT) - since 2013
Volume in USD (price x number of shares), data since 2013Sarepta Therapeutics (SRPT) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2025 | £10.06 M | -76.01% |
| 2024 | £41.97 M | 24.73% |
| 2023 | £33.65 M | 66.59% |
| 2022 | £20.2 M | -64.04% |
| 2021 | £56.17 M | -40.62% |
| 2020 | £94.6 M | -66.33% |
| 2019 | £0.28 B | 16.72% |
| 2018 | £0.24 B | 253.79% |
| 2017 | £68.05 M | -40.35% |
| 2016 | £0.11 B | 190.97% |
| 2015 | £39.21 M | -69.48% |
| 2014 | £0.12 B | 79.12% |
| 2013 | £71.71 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3 months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Gilead Sciences GILD | £0.16 B | £0.25 B | 🇺🇸 USA |
 Novavax NVAX | £22.55 M | £0.10 B | 🇺🇸 USA |
 Avidity Biosciences RNA | £7.32 M | £22.04 M | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | £3.55 M | £4.77 M | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | £9.22 M | £39.77 M | 🇺🇸 USA |
 PTC Therapeutics
PTCT | £1.16 M | £31.56 M | 🇺🇸 USA |
 Insmed INSM | £10.88 M | £64.26 M | 🇺🇸 USA |